<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="131366">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01391819</url>
  </required_header>
  <id_info>
    <org_study_id>112994</org_study_id>
    <nct_id>NCT01391819</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Incidence, Clinical Characteristics and Economic Burden of Dengue in Brazilian Children</brief_title>
  <official_title>An Epidemiological Study to Evaluate the Incidence, Clinical Characteristics and Economic Burden of Dengue in Brazilian Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The aim of this study is to establish an active surveillance in order to generate dengue
      disease burden estimates including incidence rates, prevalence data, clinical presentation
      and cost of illness in Forteleza (Brazil).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective cohort study.

      The study period initially planned to be two years, is extended by one year to cover one
      additional dengue season.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of laboratory confirmed symptomatic dengue infection cases</measure>
    <time_frame>At Year 1 (2012)</time_frame>
    <description>Laboratory-confirmed dengue infection refers to suspected symptomatic dengue cases with positive dengue virus identification or serologic evidence of dengue infection through Reverse Transcriptase quantitative Polymerase Chain Reaction (RT-qPCR) from first blood sample or anti-dengue Immunoglobulin type M/G (IgM/G) seroconversions between first and second blood sampling.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of laboratory confirmed symptomatic dengue infection cases</measure>
    <time_frame>At Year 2 (2013)</time_frame>
    <description>Laboratory-confirmed dengue infection refers to suspected symptomatic dengue cases with positive dengue virus identification or serologic evidence of dengue infection through Reverse Transcriptase quantitative Polymerase Chain Reaction (RT-qPCR) from first blood sample or anti-dengue Immunoglobulin type M/G (IgM/G) seroconversions between first and second blood sampling.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of laboratory confirmed symptomatic dengue infection cases</measure>
    <time_frame>At Year 3 (2014)</time_frame>
    <description>Laboratory-confirmed dengue infection refers to suspected symptomatic dengue cases with positive dengue virus identification or serologic evidence of dengue infection through Reverse Transcriptase quantitative Polymerase Chain Reaction (RT-qPCR) from first blood sample or anti-dengue Immunoglobulin type M/G (IgM/G) seroconversions between first and second blood sampling.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with Immunoglobulin type G (IgG) antibodies against dengue</measure>
    <time_frame>From Day 0 to Year 3</time_frame>
    <description>Immune response against dengue was assessed via the Enzyme-linked Immunosorbent Assay (ELISA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with asymptomatic dengue primary infection</measure>
    <time_frame>From Day 0 to Year 3</time_frame>
    <description>Asymptomatic dengue primary infection was defined as a documented seroconversion (anti-dengue IgG antibodies) between two sequential sera samples obtained during the scheduled visits, without suspicion of dengue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with laboratory confirmed and probable dengue cases</measure>
    <time_frame>From Year 0 to Year 3</time_frame>
    <description>A case of primary or secondary symptomatic dengue infection was defined as laboratory confirmed or probable symptomatic dengue case whose previous sample collected at scheduled Visits 1- 4 (Day 0- Year 3) to detect anti-dengue IgG antibodies was seronegative or seropositive, respectively.
A probable dengue case was defined as a suspected symptomatic dengue case with the following laboratory findings: -anti-dengue IgM or anti-dengue IgG positivity in at least one sample (in either blood sample 1 or 2); no evidence of viremia (negative dengue virus identification through RT-qPCR) in blood sample 1; and no evidence of anti-dengue Ig M or IgG seroconversion between blood sample 1 and blood sample 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of dengue infection cases by virus type</measure>
    <time_frame>From Day 0 to Year 3</time_frame>
    <description>Among virus types causing dengue infection were DENV-4 in 2012 and 2013 and DENV-1 in 214, as assessed by PCR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of primary laboratory confirmed symptomatic dengue infection cases</measure>
    <time_frame>From Day 0 to Year 3</time_frame>
    <description>Primary symptomatic dengue infection cases are defined as laboratory confirmed symptomatic dengue cases whose previous sample collected at scheduled visits to detect anti-dengue IgG antibodies were seronegative or seropositive, respectively. Analysis was done by calendar year and age strata.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of secondary laboratory confirmed symptomatic dengue infection cases</measure>
    <time_frame>From Day 0 to Year 3</time_frame>
    <description>Secondary symptomatic dengue infection cases are defined as laboratory confirmed symptomatic dengue cases whose previous sample collected at scheduled visits to detect anti-dengue IgG antibodies were seronegative or seropositive, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of working days missed of primary care giver 1 and 2</measure>
    <time_frame>Up to Day 35 post laboratory confirmed dengue onset</time_frame>
    <description>The number of days off work from caregiver were recorded as part of health economics indirect resource utilization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caregiver absenteeism associated with subject dengue illness</measure>
    <time_frame>Up to Day 35 post laboratory confirmed dengue onset</time_frame>
    <description>The number of suspected dengue infections with primary caregivers missing from work was recorded as part of health economics indirect resource utilization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of school days missed by subjects</measure>
    <time_frame>Up to Day 35 post laboratory confirmed dengue onset</time_frame>
    <description>The number of school days missed by subjects due to dengue infection were recorded as part of the dengue active surveillance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects absenteeism associated with dengue illness</measure>
    <time_frame>Up to Day 35 post laboratory confirmed dengue onset</time_frame>
    <description>The number of suspected dengue infections with subjects missing from school due to dengue infection were recorded as part of the dengue active surveillance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with serious adverse events (SAEs)</measure>
    <time_frame>From Day 0 to Year 3</time_frame>
    <description>Serious adverse events (SAEs) assessed include medical occurences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Direct medical resource associated with suspected dengue cases</measure>
    <time_frame>From Day 0 to Year 3</time_frame>
    <description>Direct medical resource included hospitalization, stay in intensive care units (ICU), medications, diagnostic and therapeutic procedures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospitalization days due to suspected dengue cases</measure>
    <time_frame>From Day 0 to Year 3</time_frame>
    <description>Length of hospitalization was part of the direct medical resource, associated with dengue infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dengue infection episodes related temperature</measure>
    <time_frame>From Day 0 to Year 3</time_frame>
    <description>Temperature, expressed in degrees Celsius (Â°C), was among symptoms of symptomatic dengue infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of dengue episodes with any temperature interval</measure>
    <time_frame>From Day 0 to Year 3</time_frame>
    <description>Temperature intervals assessed varied from hipotermia 33.5 to 36.4 degrees celsius (Â°C), to normal temperature 36.5-35.9 Â°C and hipertermia 37 - 39.9 Â°C, or were unknown.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of dengue episodes associated with clinical symptoms</measure>
    <time_frame>From Day 0 to Year 3</time_frame>
    <description>Dengue related clinical symptoms included general symptoms, digestive symptoms, respiratory symptoms, hemorrhagic symptoms and any other signs among first symptoms.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2117</enrollment>
  <condition>Dengue</condition>
  <arm_group>
    <arm_group_label>Study cohort</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Children age 5 to 13 years at the time of enrollment, selected from schools in Fortaleza.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Data collection</intervention_name>
    <description>Socio-demographic information, medical history, yellow fever vaccination history and dengue suspicion data collection.</description>
    <arm_group_label>Study cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood sample collection</intervention_name>
    <description>A blood sample will be collected at each of the three scheduled study visits and any time during the study that dengue is suspected. Samples collected at scheduled visits will be tested for anti-dengue antibodies. Samples collected at visits for dengue suspicion will be tested for dengue diagnosis.</description>
    <arm_group_label>Study cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female between 5 and 13 years of age (including children at least 5 years of
             age and excluding children who reached their fourteenth birthday) at the time of
             enrollment.

          -  Written informed consent (and assent when applicable).

          -  Subjects who the investigator believes that they and/or their parent(s)/LAR can and
             will comply with the requirements of the protocol (e.g. willingness to do a hospital
             visit in case of dengue suspicion, willingness to attend the study hospital return
             for follow-up visits, able to observe for signs of dengue, understand how to take a
             temperature, etc).

          -  Subjects who plan to attend one of the study schools for two school years following
             enrollment.

        Exclusion Criteria:

          -  Subjects planning to move from the study area during the two school years following
             enrollment.

          -  Child in care.

          -  Enrollment in another study that would conflict with the current study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>13 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fortaleza</city>
        <state>CearÃ¡</state>
        <zip>60430 160</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 15, 2017</lastchanged_date>
  <firstreceived_date>July 8, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Brazil</keyword>
  <keyword>Incidence</keyword>
  <keyword>Dengue virus</keyword>
  <keyword>Dengue</keyword>
  <keyword>Dengue infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dengue</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
